𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Melatonin Receptor (MT1) and Nestin Coexpression: an indicator of more advanced breast cancer?

✍ Scribed by O. Rögelsperger; C. Ekmekcioglu; M. Svoboda; R. Königsberg; M. Klimpfinger; W. Jäger; T. Thalhammer

Book ID
119598896
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
89 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Signal transduction of the melatonin rec
Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields
✍ Rainer Girgert; Volker Hanf; Günter Emons; Carsten Gründker 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 1 views

## Abstract The growth of estrogen‐receptor positive breast cancer cells is inhibited by the pineal gland hormone, melatonin. Concern has been raised that power‐line frequency and microwave electromagnetic fields (EMFs) could reduce the efficiency of melatonin on breast cancer cells. In this study

Plasma prolactin as an indicator of dise
Plasma prolactin as an indicator of disease progression in advanced breast cancer
✍ Joytsna M. Bhatavdekar; Neelam G. Shah; Damodar B. Balar; Devendra D. Patel; Ani 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Serial plasma prolactin levels were measured in 144 breast cancer patients (premenopausal [PR-MI, N = 64; postmenopausal [PO-MI, N = 80) and compared with respective controls. Patients with breast cancer were grouped into those who (1) developed distant metastasis, (2) developed local recurrence, (3

Hyperprolactinemia is an indicator of pr
Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer
✍ Wilhelm Holtkamp; Gerd Arno Nagel; Hans-Erik Wander; Helmut Franz Rauschecker; D 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 French ⚖ 573 KB

## Abstract In a long‐term follow‐up study, prolactin levels were measured in 149 patients with advanced metastatic breast cancer. Control groups included 221 patients with primary operable breast cancer and 150 women with benign breast disease. Hyperprolactinemia (>1,000 mlU/l; HYPRL) occurs in 44